First Quadrant’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q1 | – | Sell |
-41,897
| Closed | -$11.6M | – | 351 |
|
|
2021
Q4 | $11.6M | Hold |
41,897
| – | – | 1.24% | 11 |
|
|
2021
Q3 | $9.68M | Hold |
41,897
| – | – | 1.13% | 11 |
|
|
2021
Q2 | $9.62M | Hold |
41,897
| – | – | 1.1% | 12 |
|
|
2021
Q1 | $7.83M | Hold |
41,897
| – | – | 0.83% | 14 |
|
|
2020
Q4 | $7.07M | Sell |
41,897
-3,022
| -7% | -$451K | 0.71% | 17 |
|
|
2020
Q3 | $6.65M | Sell |
44,919
-7,633
| -15% | -$1.18M | 0.85% | 15 |
|
|
2020
Q2 | $8.63M | Buy |
52,552
+18,071
| +52% | +$2.77M | 1.16% | 9 |
|
|
2020
Q1 | $4.78M | Buy |
34,481
+32,981
| +2,199% | +$4.53M | 0.7% | 27 |
|
|
2019
Q4 | $197K | Hold |
1,500
| – | – | 0.02% | 407 |
|
|
2019
Q3 | $168K | Hold |
1,500
| – | – | 0.02% | 436 |
|
|
2019
Q2 | $166K | Hold |
1,500
| – | – | 0.01% | 535 |
|
|
2019
Q1 | $195K | Sell |
1,500
-2,168
| -59% | -$264K | 0.01% | 495 |
|
|
2018
Q4 | $424K | Buy |
3,668
+2,168
| +145% | +$242K | 0.03% | 388 |
|
|
2018
Q3 | $161K | Hold |
1,500
| – | – | ﹤0.01% | 652 |
|
|
2018
Q2 | $128K | Hold |
1,500
| – | – | ﹤0.01% | 628 |
|
|
2018
Q1 | $116K | Hold |
1,500
| – | – | ﹤0.01% | 679 |
|
|
2017
Q4 | $127K | Hold |
1,500
| – | – | ﹤0.01% | 783 |
|
|
2017
Q3 | $128K | Sell |
1,500
-4,043
| -73% | -$332K | ﹤0.01% | 771 |
|
|
2017
Q2 | $456K | Buy |
5,543
+2,688
| +94% | +$219K | 0.01% | 550 |
|
|
2017
Q1 | $240K | Buy |
2,855
+1,355
| +90% | +$109K | ﹤0.01% | 622 |
|
|
2016
Q4 | $110K | Sell |
1,500
-218,011
| -99% | -$16.2M | ﹤0.01% | 696 |
|
|
2016
Q3 | $17.6M | Buy |
219,511
+218,011
| +14,534% | +$17.4M | 0.37% | 85 |
|
|
2016
Q2 | $118K | Hold |
1,500
| – | – | ﹤0.01% | 639 |
|
|
2016
Q1 | $108K | Buy |
+1,500
| New | +$113K | ﹤0.01% | 637 |
|
|
2015
Q1 | – | Sell |
-3,300
| Closed | -$228K | – | 771 |
|
|
2014
Q4 | $228K | Hold |
3,300
| – | – | ﹤0.01% | 521 |
|
|
2014
Q3 | $214K | Sell |
3,300
-322,500
| -99% | -$20.4M | ﹤0.01% | 545 |
|
|
2014
Q2 | $20.3M | Sell |
325,800
-242,500
| -43% | -$14.5M | 0.45% | 65 |
|
|
2014
Q1 | $33.5M | Buy |
568,300
+274,000
| +93% | +$15.3M | 0.76% | 33 |
|
|
2013
Q4 | $15M | Buy |
294,300
+1,300
| +0.4% | +$65.1K | 0.35% | 93 |
|
|
2013
Q3 | $14.7M | Buy |
293,000
+287,700
| +5,428% | +$15.1M | 0.37% | 86 |
|
|
2013
Q2 | $260K | Buy |
+5,300
| New | +$288K | 0.01% | 511 |
|
Other funds holding LLY
First Quadrant's LLY Position: Q1 2022 in Review
First Quadrant sold out of Eli Lilly (LLY) in Q1 2022, closing a stake of 41,897 shares — an estimated $11.6M sold.
First Quadrant first reported a position in LLY in Q2 2013 and held it in 31 quarters. The position peaked at $33.5M in Q1 2014. 2,346 funds tracked by Wall St. Rank hold LLY as of Q1 2022.
- First Quadrant reported no remaining Eli Lilly position as of Q1 2022 after selling out during the quarter.
- First Quadrant sold 41,897 Eli Lilly shares in Q1 2022, an estimated $11.6M.
- First Quadrant first reported a position in Eli Lilly in Q2 2013 and held it in 31 quarters.
- First Quadrant's Eli Lilly position peaked at $33.5M in Q1 2014.
- 2,346 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2022.
Based on First Quadrant's 13F filing for Q1 2022, filed 21 Apr 2022.